Navigation Links
QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
Date:5/21/2009

Oral Ruling Issued in Massachusetts General Hospital Lawsuit

VANCOUVER, May 21 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that on May 21, 2009, the District Court of Massachusetts ("District Court") issued an oral ruling on QLT's Motion to Dismiss all the claims filed by the General Hospital Corporation, doing business as Massachusetts General Hospital ("MGH") in its lawsuit against QLT. In the oral decision, the District Court dismissed all of the claims filed by MGH except that made under Massachusetts General Law chapter 93A, a consumer protection law which makes "unfair or deceptive acts or practices in the conduct of any trade or commerce" unlawful. QLT's Motion to Dismiss was filed with the District Court on March 17, 2009. We expect that the District Court will formally enter its ruling on the court's docket in the near future.

In the oral decision, the District Court also dismissed MGH's motion to remand the case back to the Superior Court of the Commonwealth of Massachusetts ("Massachusetts State Court"), where MGH had originally filed its complaint.

The decision of the District Court means that MGH can continue its lawsuit against QLT in the District Court only on the claim made under Massachusetts General Law chapter 93A. Under the direction of the District Court, QLT and MGH will now begin to schedule discovery on this claim.

MGH filed its lawsuit against QLT on February 12, 2009, in the Massachusetts State Court. In its complaint, MGH asserted claims for breach of contract, breach of the implied covenant of good faith and fair dealing, violation of Massachusetts Chapter 93A Sections 2 and 11, unjust enrichment, and for a declaratory judgment.

In essence, MGH alleged that, in 1998, it entered into a written agreement with QLT that (a) called for QLT to pay MGH a royalty of 0.5% on sales of Visudyne(R) in the United States and Canada, and (b) included a "most favored nations" clause that required QLT to increase that royalty rate if QLT entered into a license agreement with Massachusetts Eye and Ear Infirmary ("MEEI") for certain patent rights at a higher rate. As previously announced, MEEI was recently awarded a 3.01% royalty rate, on worldwide sales of Visudyne, in a highly contested legal action against QLT involving claims for unjust enrichment. MGH alleged that the "most favored nations" clause was triggered by the judgment on this jury verdict. QLT disagreed, and moved to dismiss all of MGH's claims, with prejudice. QLT intends to vigorously contest the claim remaining in this lawsuit.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at www.qltinc.com.

    QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.
    Atrigel is a registered trademark of QLT USA, Inc.
    Visudyne is a registered trademark of Novartis AG.
    Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by QLT's use of words such as, "expect," "plans," "estimates," "intends," "believes" and similar expressions that do not relate to historical matters. Such forward-looking statements are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the oral ruling in QLT's Motion to Dismiss may be reviewable, which review could result in a decision more or less favorable to QLT, and other factors as described in detail in QLT's Annual Information Form and Annual Report on Form 10-K, quarterly reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. All forward-looking statements in this press release are made as of today, based upon information known to QLT as of the date hereof. QLT assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that indicated results or events will not be realized.


'/>"/>
SOURCE QLT Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders
2. Secretary Shinseki Announces $215 Million in Projects for Rural Veterans
3. Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades
4. Medstrat Announces Integration of Echoes With MacPractices EMR
5. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
6. Cord Blood America, Inc. Announces 2009 First Quarter Results
7. Universal Health Services, Inc. Announces Marc D. Miller Named President of Universal Health Services
8. Universal Health Services, Inc. Announces Dividend
9. TouchMark Announces New Sales Representative
10. Sagent Pharmaceuticals Announces Extension of Series A Financing
11. Covidien announces milestone placement in remote respiratory monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... CloudLIMS, joins an elite ... Life Sciences Tech Solution Providers list of 2016 by CIOReview. , In a deliberate ... Life Sciences Tech Solution Providers 2016 has been concluded with. The positioning is based ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group ... Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies ... inspire all those who knew him. The award named for him is not given ...
(Date:5/25/2016)... ... May 25, 2016 , ... Afrimesure specializes in providing clients ... to food and HVAC facilities. Their knowledgeable staff also takes care of the ... applications, Afrimesure offers a variety of MadgeTech systems available for sterilization and temperature ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad ... annual Medical and Prescription Drug survey , an employee benefits ... which was conducted in December 2015, indicates that employers are turning to consumer ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... For more than fifty years, we've suffered ... we changed our diets to conform to the latest nutritional advice – advice that was ... the NIH, more than 2 in 3 American adults are considered to be overweight and ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 Cirujanos ... para ayudar a los médicos a compartir sus mejores ... a escala mundial. Profesionales médicos de Europa, África, ... han apuntado a la aplicación, que combina la transmisión ... entorno totalmente seguro. Educación   "Imagine ...
(Date:5/24/2016)... , May 24, 2016  Diana Russell suffers from ... organs from the inside out.  This disease has put ... on her children and grandchildren to leave her home.  ... Diana,s family cannot haul the wheelchair.  So if there ... car, and Diana is left to wait for the ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
Breaking Medicine Technology: